C57BL/6JCya-Laptm4aem1/Cya
Common Name
Laptm4a-KO
Product ID
S-KO-03278
Backgroud
C57BL/6JCya
Strain ID
KOCMP-17775-Laptm4a-B6J-VA
When using this mouse strain in a publication, please cite “Laptm4a-KO Mouse (Catalog S-KO-03278) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
Basic Information
Strain Name
Laptm4a-KO
Strain ID
KOCMP-17775-Laptm4a-B6J-VA
Gene Name
Product ID
S-KO-03278
Gene Alias
MTP, Mtrp, LAPTM4, mKIAA0108
Background
C57BL/6JCya
NCBI ID
Modification
Conventional knockout
Chromosome
Chr 12
Phenotype
Datasheet
Application
--
Strain Description
Ensembl Number
ENSMUST00000020909
NCBI RefSeq
NM_008640
Target Region
Exon 2
Size of Effective Region
~0.8 kb
Overview of Gene Research
Laptm4a, short for lysosomal-associated protein transmembrane 4A, is a protein-coding gene. It is involved in multiple cellular processes such as lysosomal function regulation and protein-protein interactions. It has been implicated in pathways related to glycolipid biosynthesis, endocytosis, and protein degradation, which are crucial for maintaining normal cellular homeostasis [2,3,4,5].
In glioma, Laptm4a is up-regulated and associated with poor prognosis. It may influence metastasis through the epithelial-mesenchymal transition (EMT) pathway. High Laptm4a-expressing glioma patients are sensitive to doxorubicin [1]. In HeLa cells, disruption of Laptm4a reduces globotriaosylceramide (Gb3) biosynthesis, affecting the post-transcriptional regulation of Gb3 synthase activity [3]. In HEK293 cells, overexpression of Laptm4a negatively regulates the function of human organic cation transporter 2 (hOCT2) by influencing its trafficking to/from the cell membrane [2].
In summary, Laptm4a plays important roles in glycolipid regulation, protein-protein interactions, and cell-membrane trafficking. Its dysregulation is associated with glioma, highlighting its potential as a biomarker and therapeutic target for this disease. The functional studies on Laptm4a using in vitro models have provided insights into its role in specific biological processes relevant to disease conditions [1,2,3].
References:
1. Ding, Yongqi, Jiang, Yike, Zeng, Hong, Xiong, Chengfeng, Huang, Da. 2024. Identification of a robust biomarker LAPTM4A for glioma based on comprehensive computational biology and experimental verification. In Aging, 16, 6954-6989. doi:10.18632/aging.205736. https://pubmed.ncbi.nlm.nih.gov/38613802/
2. Grabner, A, Brast, S, Sucic, S, Schlatter, E, Ciarimboli, G. 2011. LAPTM4A interacts with hOCT2 and regulates its endocytotic recruitment. In Cellular and molecular life sciences : CMLS, 68, 4079-90. doi:10.1007/s00018-011-0694-6. https://pubmed.ncbi.nlm.nih.gov/21553234/
3. Yamaji, Toshiyuki, Sekizuka, Tsuyoshi, Tachida, Yuriko, Kuroda, Makoto, Hanada, Kentaro. 2019. A CRISPR Screen Identifies LAPTM4A and TM9SF Proteins as Glycolipid-Regulating Factors. In iScience, 11, 409-424. doi:10.1016/j.isci.2018.12.039. https://pubmed.ncbi.nlm.nih.gov/30660999/
4. Zhang, Weichao, Yang, Xi, Chen, Liang, Wang, Yanzhuang, Li, Ming. 2021. A conserved ubiquitin- and ESCRT-dependent pathway internalizes human lysosomal membrane proteins for degradation. In PLoS biology, 19, e3001361. doi:10.1371/journal.pbio.3001361. https://pubmed.ncbi.nlm.nih.gov/34297722/
5. Tian, Songhai, Muneeruddin, Khaja, Choi, Mei Yuk, Adam, Rosalyn M, Dong, Min. 2018. Genome-wide CRISPR screens for Shiga toxins and ricin reveal Golgi proteins critical for glycosylation. In PLoS biology, 16, e2006951. doi:10.1371/journal.pbio.2006951. https://pubmed.ncbi.nlm.nih.gov/30481169/
Quality Control Standard
Sperm Test
Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.
Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.
Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
